Uncategorized
Gemini Therapeutics Appoints Dr. Tuyen Ong as Independent Director
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that Dr. Tuyen Ong has been appointed to serve as an independent member of its Board of Directors. “Tuyen has a demonstrated record of tangible successes in ophthalmology innovation, and we are confident that his strategic guidance will benefit our clinical